BMJ  2007;335:400 (25 August), doi:10.1136/bmj.39309.704016.BD

Views & reviews

Personal views

The Alzheimer's Society, drug manufacturers, and public trust

James Lind Initiative, Oxford OX2 7LG

The first 150 words of the full text of this article appear below.

For about five years before he died, my father had Alzheimer's disease. When it was first diagnosed we asked him how he wished his condition to be described when other people asked us about his health. He chose "bewildered"; and, indeed, bewilderment characterised his slow decline over the next five years. By far the most important part of his care was the loving support he received from a carer, who helped our family to cope.

We briefly considered the possibility of drug treatment at one point. The particular drug that we looked at caused diarrhoea in some patients, and that was not going to be welcome in someone who was already incontinent of urine and faeces. But the main problem was that we couldn't interpret the outcome measures from research studies (often scales of some sort). Although sufficient to secure drug marketing licences they had little practical meaning in my . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Alzheimer's Society replies to Iain Chalmers

Neil Hunt
BMJ 2007 335: 541. [Extract] [Full Text] [PDF]

Nice feedback

Fiona Godlee
BMJ 2007 335: 0. [Extract] [Full Text]

NICE's cost effectiveness threshold

John Appleby, Nancy Devlin, and David Parkin
BMJ 2007 335: 358-359. [Extract] [Full Text] [PDF]

High Court upholds NICE decision to limit treatments for Alzheimer's disease

Owen Dyer
BMJ 2007 335: 319. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Poole, C., Agrawal, S., Currie, C. J (2007). Let cost effectiveness models be open to scrutiny. BMJ 335: 735-735 [Full text]  
• Chalmers, I. (2007). Addressing uncertainties about the effects of treatments offered to NHS patients: whose responsibility?. JRSM 100: 440-441 [Full text]  

Rapid Responses:

Read all Rapid Responses

There are no winners and losers in a case that involves the only drug treatments available for people with dementia

Andrew Ketteringham
bmj.com, 24 Aug 2007 [Full text]

The Alzheimer's Society and public trust

Iain Chalmers
bmj.com, 26 Aug 2007 [Full text]

Alzheimers society and drug promotion

Miranda Mugford
bmj.com, 28 Aug 2007 [Full text]

Role of Alzheimer Society

Hugh Rickards
bmj.com, 31 Aug 2007 [Full text]

Meaningful Trial Outcomes

Arun S. Nanivadekar
bmj.com, 15 Sep 2007 [Full text]

NICE cost-effectiveness models should be open to scrutiny

Chris D Poole, et al.
bmj.com, 24 Sep 2007 [Full text]

Obtaining the evidence - new opportunities for clinical trials in neurodegenerative diseases

John Zajicek, et al.
bmj.com, 26 Sep 2007 [Full text]

Online poll

Find out more >>